Marvel Biosciences CorpOTCQB:MBCOFView on Canadian Exchange
- LAST PRICE0.1076
- TODAY'S CHANGE (%)0.0029 (2.7417%)
- Bid / Lots0.0851/ 100
- Ask / Lots0.1300/ 150
- Open / Previous Close0.1076 / 0.1047
- Day Range
- 52 Week Range
- Volume11,500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MBCOF |
|---|
Nov 21, 2024
Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer's Research, from 7:01AM ET on Thursday Nov 21, 2024 by Dow Jones
7:01AM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 15, 2024
Life Sciences Investor Forum: Presentations Now Available for Online Viewing, from 8:35AM ET on Friday Nov 15, 2024 by Dow Jones
8:35AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 13, 2024
Marvel Biosciences Corp. to Present at the Life Sciences Investor Forum November 14th, from 8:35AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:35AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 7, 2024
Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome, from 7:02AM ET on Thursday Nov 07, 2024 by Dow Jones
7:02AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Marvel Biosciences Corp | 7.4M | --- | --- |
Company Information
Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The Company is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.
Contact Information
- Headquarters
- Suite 420, 505 8th Avenue S.W.CALGARY, AB, Canada T2P 1G2
- Phone
- 403-770-2469
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.8M |
Marvel Biosciences Corp does not pay a dividend. | |
Beta | 0.75 |
EPS | $-0.05 |
Book Value | $-0.04 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
